Research overview
What is Semax?
Semax is based on the ACTH(4–7) sequence with a Pro-Gly-Pro extension. It is different from Selank, which derives from a tuftsin-related sequence. A supplier vial should not inherit the manufacturing or claims of another regional product.
What has research examined?
Russian-language ischemic-stroke clinical reports examined Semax under local research conditions, including clinical and electrophysiological outcomes. Another study reported BDNF plasma changes at different rehabilitation stages. Biomarker changes cannot establish broad neuroprotection, and FDA identifies inadequate safety information for proposed compounded Semax.
These regional reports do not establish standardized U.S. therapeutic efficacy, exact-vial identity, or safe self-administration. No stroke treatment, amount, or preparation is suggested.
Research references
- Semax in the acute period of hemispheric ischemic strokeRussian-language clinical research
- Semax across ischemic-stroke rehabilitation stagesRussian-language clinical research
- Certain bulk substances that may present significant safety risksU.S. Food and Drug Administration
Calculation boundary
The cited clinical studies investigated specific non-vial formulations; FDA flags aggregation/impurity and insufficient route-specific human safety information for proposed compounded Semax.